Navigation Links
Heart failure in older breast cancer patients linked to medication
Date:11/14/2012

Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.

The researchers conducted this study because older women who are at higher risk of decreased heart function, were often excluded from randomized clinical trials of trastuzumab, which is used to treat breast tumors that over-express human epidermal growth factor receptor-2 (HER-2). Past clinical trials in younger, healthier women showed improved survival, but also increased heart complications linked to trastuzumab, especially when combined with a frequently used therapy called anthracycline chemotherapy.

"We observed an even higher risk of heart failure or cardiomyopathy after trastuzumab therapy than those in past clinical trials," said lead author Jersey Chen, M.D., assistant professor of cardiology at Yale University School of Medicine and a member of the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale.

The Yale COPPER team examined the association between the use of adjuvant trastuzumab and anthracycline therapy and heart failure and cardiomyopathy, the most serious cardiotoxic complications, in 45,536 female Medicare beneficiaries with early-stage breast cancer. The use of trastuzumab has increased over time from 2.6% of the women who received any adjuvant therapy in 2000 to 22.6% in 2007.

The team found that compared with patients who received no adjuvant chemotherapy or trastuzumab; use of trastuzumab was associated with a 14% higher adjusted incidence rate for heart failure or cardiomyopathy over three years. Patients who received both trastuzumab and anthracycline had a 23.8% higher rate, and those treated with anthracycline chemotherapy alone had a 2.1% higher rate of heart failure or cardiomyopathy events over three years.

"Further study is needed to fully understand the benefits and risks of trastuzamab when they are used in the real-world population," said Cary Gross, senior author of the study and director of the COPPER Center.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Related medicine news :

1. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
2. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
3. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
4. In children born with severe heart defect, surgical management has little effect on neuro outcomes
5. Invasive heart test being dramatically overused, Stanford study shows
6. Heart failure patients with diabetes may benefit from higher glucose levels
7. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
8. EKG Heart Test May Predict Risk in Older Adults
9. Common Blood Pressure Drug Safe for Heart Failure: Study
10. Spouses of Cancer Patients May Have Raised Risk of Heart Disease, Stroke
11. SMART heart eases heart ache, targets cardiac patients emotional well-being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 26, 2017 , ... Global healthcare company Novo Nordisk, renewed ... company’s commitment to the world’s first all-diabetes professional cycling team to a total ... partnered with the professional cycling team Team Type 1 to create Team Novo ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... CGL Electronic ... first office under its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, ... veterans Remo Patitucci and Jon McCormack, both of whom have creative business development methods, ...
(Date:9/26/2017)... ... September 26, 2017 , ... As the holiday season nears, ... https://dealfeed.sutlr.com . People are constantly trying to find tips and stories for products and ... feed brings you the top trending deals. The deals are organized by categories so ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Device Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification      , ... Manufacturers must prove that their equipment, operations and processes all work the ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Founded as ... decades growing into an innovative leader in special education. In 2018, Glenholme will ... , Glenholme, formerly a world renowned horse farm for Hackney show ponies, was generously ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
Breaking Medicine Technology: